Berge LAM, Andreassen BK, Stenehjem JS, et al. - Using the Cancer Registry of Norway, researchers assessed the links between use of immunomodulating drugs and risk of melanoma, at a nationwide population level. They selected patients aged 18– 85 with a first primary cutaneous melanoma diagnosed in 2007– 2015 (n = 12,106). Elevated risk of melanoma was observed in relation to use of ≥ 8 prescriptions of immunosuppressants vs ≤ 1 prescription. Similar links were evident for subgroups of immunosuppressants: drugs typically prescribed to organ transplant recipients (OTRs) and methotrexate. There was no link between use of corticosteroids and melanoma risk. Findings demonstrated that use of immunosuppressants was positively associated with the risk of melanoma, with the highest risk noted for drugs prescribed to OTRs.